Morsbach

Researchers are investigating sovateltide, a new drug that targets ETB receptors, for treating acute cerebral ischemic stroke (ACIS), a condition caused by a blocked blood vessel in the brain leading to brain tissue damage. ACIS is the most common type of stroke and a serious emergency with limited treatment options. Current standard treatment with tissue plasminogen activator (t-PA) has a narrow time window and limited success in fully resolving stroke effects. Sovateltide has shown promise in animal studies and early human trials by promoting brain repair and improving neurological outcomes. The study compares sovateltide treatment alongside standard care to a placebo (normal saline) in patients who recently experienced ACIS. Participants will receive the study drug within 24 hours of stroke symptom onset. This phase III trial is randomized, double-blind, and placebo-controlled, conducted across multiple centers in the United States, Canada, the United Kingdom, and Europe. The trial builds on positive results from earlier phase II and III studies conducted in India. Participants will be followed for 90 days after treatment to assess recovery using scales that measure disability and neurological function. Researchers will monitor safety and effectiveness by evaluating participants' abilities and stroke outcomes, including the modified Rankin Scale score. The trial aims to provide further evidence on whether sovateltide can improve recovery and function after acute ischemic stroke when added to standard treatment.